European Journal of Clinical Pharmacology

, Volume 75, Issue 5, pp 639–645 | Cite as

Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial

  • Hassan Seddik
  • Hanae BoutallakaEmail author
  • Ilham Elkoti
  • Fouad Nejjari
  • Reda Berraida
  • Sanaa Berrag
  • Khaoula Loubaris
  • Sara Sentissi
  • Ahmed Benkirane
Clinical Trial



To determine the effect of Saccharomyces boulardii CNCM I-745 (S. boulardii) plus sequential therapy on Helicobacter pylori (H. pylori) eradication rate.


This open-label prospective study randomized (1:1) patients with confirmed H. pylori infection to standard sequential therapy of twice-daily (bid) omeprazole 20 mg plus amoxicillin 1 g for 5 days, followed by bid omeprazole 20 mg, clarithromycin 500 mg and metronidazole 500 mg for the next 5 days (control group), or sequential therapy plus bid S. boulardii 250 mg (experimental group). Adverse events (AEs) were recorded throughout the study, and the H. pylori eradication rate was determined 4 weeks after treatment.


The study was conducted from May 2013 to May 2016 and included 199 patients (51.3% male; mean age 44.6 ± 13.6 years). The H. pylori eradication rate was higher in the experimental group than the control group (86.0% vs. 74.7%; P = 0.02). Compared with the control group, patients in the experimental group experienced a significantly lower overall incidence of AEs (17.0% vs. 55.7%; p < 0.001) and the incidence of antibiotic-associated diarrhea (2.0% vs. 46.4%; P = 0.02). The experimental group showed improved treatment compliance over the 10-day study period compared with the control group (95.0% vs. 91.2%, P < 0.001).


Addition of S. boulardii to sequential therapy improved H. pylori eradication rate and reduced the incidence of treatment-associated AEs in Moroccan patients with H. pylori infection.


Antibiotic-induced diarrhea Helicobacter pylori H. pylori eradication rate Saccharomyces boulardii Sequential treatment Treatment compliance 



The authors thank Nishad Parkar, PhD, of Springer Healthcare Communications for technical and English editing of the manuscript prior to submission. This medical writing assistance was funded by Biocodex.

Author contributions

Hassan Seddik was responsible for study concept and planning and supervised the statistical analysis and redaction of the manuscript. Hanae Boutallaka was involved in performing the statistical analysis and writing the manuscript, with input from all authors. Fouad Nejjari, Reda Berraida, Khaoula Loubaris, Ilham Elkoti, Sanaa Berrag and Sara Sentissi were involved in patient enrollment and data collection and were involved in the preparation of the manuscript. Ahmed Benkirane was involved in conducting and supervising the study.

Support was provided by Biocodex, France.

Compliance with ethical standards

Informed consent statement

All patients included in the study provided written informed consent before the study commenced.

Conflict of interest

The authors have no conflicts of interest to declare.

CONSORT 2010 statement

The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.


  1. 1.
    Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, Malfertheiner P, Graham DY, Wong VWS, Wu JCY, Chan FKL, Sung JJY, Kaplan GG, Ng SC (2017) Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 153(2):420–429. CrossRefPubMedGoogle Scholar
  2. 2.
    Sjomina O, Heluwaert F, Moussata D, Leja M (2017) Helicobacter pylori infection and nonmalignant diseases. Helicobacter 22(Suppl 1).
  3. 3.
    Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345(11):784–789. CrossRefPubMedGoogle Scholar
  4. 4.
    Wotherspoon A, Ortiz-Hidalgo C, Falzon M, Isaacson P (1991) Helicobacter pylori- associated gastritis and primary B-cell gastric lymphoma. Lancet 338(8776):1175–1176CrossRefGoogle Scholar
  5. 5.
    Benajah DA, Lahbabi M, Alaoui S, El Rhazi K, El Abkari M, Nejjari C, Amarti A, Bennani B, Mahmoud M, Ibrahimi SA (2013) Prevalence of Helicobacter pylori and its recurrence after successful eradication in a developing nation (Morocco). Clin Res Hepatol Gastroenterol 37(5):519–526. CrossRefPubMedGoogle Scholar
  6. 6.
    Eusebi LH, Zagari RM, Bazzoli F (2014) Epidemiology of Helicobacter pylori infection. Helicobacter 19(s1):1–5. CrossRefPubMedGoogle Scholar
  7. 7.
    Chey WD, Leontiadis GI, Howden CW, Moss SF (2017) ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol 112(2):212–239. CrossRefPubMedGoogle Scholar
  8. 8.
    Siddique O, Ovalle A, Siddique AS, Moss SF (2018) Helicobacter pylori infection: an update for the internist in the age of increasing global antibiotic resistance. Am J Med 131(5):473–479. CrossRefPubMedGoogle Scholar
  9. 9.
    World Health Organization Global priority list of antibiotic-resistant bacteria to guide research, discovery and development of new antibiotics. 27 February 2017 [cited 04 April 2018]. In: WHO Publications [Internet]. World Health Organization, Geneva. Available from:
  10. 10.
    Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM (2017) Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut 66(1):6–30. CrossRefPubMedGoogle Scholar
  11. 11.
    Kim SB, Lee SH, Kim KO, Jang BI, Kim TN (2015) Ten-day sequential therapy versus bismuth based quadruple therapy as second line treatment for Helicobacter pylori infection. Korean J Gastroenterol 66(5):261–267. CrossRefPubMedGoogle Scholar
  12. 12.
    Munteanu D, Etzion O, Ben-Yakov G, Halperin D, Eidelman L, Schwartz D, Novack V, Abufreha N, Krugliak P, Rozenthal A, Gaspar N, Moshkalo A, Dizingof V, Fich A (2017) Efficacy and safety of sequential versus quadruple therapy as second-line treatment for Helicobacter pylori infection-a randomized controlled trial. PLoS One 12(9):e0183302. CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Tong J, Ran Z, Shen J, Zhang C, Xiao S (2007) Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 25(2):155–168. CrossRefPubMedGoogle Scholar
  14. 14.
    Vandenplas Y, Brunser O, Szajewska H (2009) Saccharomyces boulardii in childhood. Eur J Pediatr 168(3):253–265. CrossRefPubMedGoogle Scholar
  15. 15.
    McFarland LV (2010) Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 16(18):2202–2222CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Szajewska H, Horvath A, Kolodziej M (2015) Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 41(12):1237–1245. CrossRefPubMedGoogle Scholar
  17. 17.
    Szajewska H, Horvath A, Piwowarczyk A (2010) Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 32(9):1069–1079. CrossRefPubMedGoogle Scholar
  18. 18.
    Seddik H, Ahid S, El Adioui T, El Hamdi FZ, Hassar M, Abouqal R, Cherrah Y, Benkirane A (2013) Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a prospective randomized study. Eur J Clin Pharmacol 69(9):1709–1715. CrossRefPubMedGoogle Scholar
  19. 19.
    Dixon MF, Genta RM, Yardley JH, Correa P (1996) Classification and grading of gastritis: the updated Sydney system. Am J Surg Pathol 20(10):1161–1181CrossRefPubMedGoogle Scholar
  20. 20.
    Savarino V, Vigneri S, Celle G (1999) The 13C urea breath test in the diagnosis of Helicobacter pylori infection. Gut 45(suppl 1):I18–I22CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S (2007) Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter 12(4):309–316. CrossRefPubMedGoogle Scholar
  22. 22.
    IBM Corp. Released (2011) IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM CorpGoogle Scholar
  23. 23.
    Zojaji H, Ghobakhlou M, Rajabalinia H, Ataei E, Jahani Sherafat S, Moghimi- Dehkordi B, Bahreiny R (2013) The efficacy and safety of adding the probiotic Saccharomyces boulardii to standard triple therapy for eradication of H. pylori: a randomized controlled trial. Gastroenterol Hepatol Bed Bench 6(Suppl 1):S99–S104PubMedPubMedCentralGoogle Scholar
  24. 24.
    Sakarya S, Gunay N (2014) Saccharomyces boulardii expresses neuraminidase activity selective for α2,3-linked sialic acid that decreases Helicobacter pylori adhesion to host cells. APMIS 122(10):941–950. CrossRefPubMedGoogle Scholar
  25. 25.
    Yang YJ, Chuang CC, Yang HB, Lu CC, Sheu BS (2012) Lactobacillus acidophilus ameliorates H. pylori-induced gastric inflammation by inactivating the Smad7 and NFkappaB pathways. BMC Microbiol 12:38. CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Zhou C, Ma FZ, Deng XJ, Yuan H, Ma HS (2008) Lactobacilli inhibit interleukin-8 production induced by Helicobacter pylori lipopolysaccharide-activated toll-like receptor 4. World J Gastroenterol 14(32):5090–5095CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Midolo PD, Lambert JR, Hull R, Luo F, Grayson ML (1995) In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol 79(4):475–479CrossRefPubMedGoogle Scholar
  28. 28.
    Bouihat N, Burucoa C, Benkirane A, Seddik H, Sentissi S, Al Bouzidi A, Elouennas M, Benouda A (2017) Helicobacter pylori primary antibiotic resistance in 2015 in Morocco: a phenotypic and genotypic prospective and multicenter study. Microb Drug Resist 23(6):727–732. CrossRefPubMedGoogle Scholar
  29. 29.
    Zullo A, De Francesco V, Bellesia A, Vassallo R, D’Angelo A, Scaccianoce G, Sacco R, Bresci G, Eramo A, Tanzilli A, Ridola L, Alvaro D, Londoni C, Brambilla G, Manta R, Di Ciaula A, Portincasa P (2017) Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice. J Gastrointestin Liver Dis 26(3):225–229PubMedGoogle Scholar
  30. 30.
    Gómez Rodríguez BJ, Castro Laria L, Argüelles Arias F, Castro Márquez C, Caunedo Álvarez Á, Romero Gómez M (2017) A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naive and previously treated patients. Rev Esp Enferm Dig 109(8):552–558. CrossRefPubMedGoogle Scholar
  31. 31.
    He L, Deng T, Luo H (2015) Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication. Intern Med 54(7):703–710. CrossRefPubMedGoogle Scholar
  32. 32.
    Kim JS, Park SM, Kim BW (2015) Sequential or concomitant therapy for eradication of Helicobacter pylori infection: a systematic review and meta-analysis. J Gastroenterol Hepatol 30(9):1338–1345. CrossRefPubMedGoogle Scholar
  33. 33.
    Kwon SB, Lee KL, Kim JS, Lee JK, Kim W, Jung YJ, Jeong JB, Kim JW, Kim BG (2010) Antibiotics-associated diarrhea and other gastrointestinal abnormal responses regarding Helicobacter pylori eradication. Korean J Gastroenterol 56(4):229–235CrossRefPubMedGoogle Scholar
  34. 34.
    Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS (2016) Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 388(10058):2355–2365. CrossRefPubMedGoogle Scholar
  35. 35.
    Bin Z, Ya-Zheng X, Zhao-Hui D, Bo C, Li-Rong J, Vandenplas Y (2015) The efficacy of Saccharomyces boulardii CNCM I-745 in addition to standard Helicobacter pylori eradication treatment in children. Pediatr Gastroenterol Hepatol Nutr 18(1):17–22. CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Zhao HM, Ou-Yang HJ, Duan BP, Xu B, Chen ZY, Tang J, You JY (2014) Clinical effect of triple therapy combined with Saccharomyces boulardii in the treatment of Helicobacter pylori infection in children. Zhongguo Dang Dai Er Ke Za Zhi 16(3):230–233PubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Gastroenterology and Digestive Endoscopy, Mohamed V Military Teaching Hospital of RabatMohamed V UniversityRabatMorocco

Personalised recommendations